查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433621

生物标记市场规模、份额和趋势分析报告：2024-2030 年按类型、产品、应用、疾病、地区和细分市场进行的预测

Biomarkers Market Size, Share & Trends Analysis Report By Type (Efficacy, Validation), By Product, By Application (Drug Discovery & Development, Personalized Medicine), By Disease, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

生物标记物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球生物标记市场规模将达到1942.1亿美元，2024年至2030年复合年增长率为13.36%。

製药和生物技术公司研发投资的增加、委外研发机构（CRO）数量的增加以及新兴国家临床试验成本的降低是该行业的主要驱动力。此外，主要企业正在利用各种策略来提高产能并扩大其产品推广。 2022 年 6 月，Page 宣布与杨森合作，利用杨森开发的 (H&E) 的 (AI) 驱动的筛检测试来筛检膀胱癌患者中可操作的 FGFR3 和 FGFR2 基因组变化。评估可能性。

癌症、糖尿病和心血管疾病等慢性病盛行率的增加预计将推动该行业的成长。据美国癌症协会称，2022年美国预计将新增190万癌症病例，609,360人死亡。世界上最常见的癌症是乳癌和肺癌。此外，根据健康指标与评估研究所 2020 年发布的报告，心血管疾病每年导致约 1,890 万人死亡。越来越多的专注于识别新诊断生物标记的研究正在推动产业成长。例如，2022年2月，日本科学家发现了两种新的诊断组织生物标记PHGDH和TRIM29，适用于恶性肋膜间质细胞瘤。

这些药物可用于快速诊断间皮瘤并帮助医生将其与其他癌症区分开来。此外，2020 年 1 月，《核子医学杂誌》上发表的一项新兴研究讨论了几种乳癌生物标记的潜力。本研究中发现的一个值得注意且易于识别的影像生物标记是 18F-FDG PET。此外，COVID-19 大流行鼓励使用生物标记物来促进疾病检测和治疗。例如，2021 年 3 月，一种名为 Tiger Tech COVID Plus Monitor 的新型基于生物标记物的筛检设备获得美国FDA核准。

该设备可用于识别 5 岁及以上人群的 COVID-19 和其他高凝血性疾病和发炎疾病的生物标记。此外，主要参与企业的各种策略性倡议预计将满足需求。例如，2022年8月，罗氏的Ventana MMR RxDx面板获得美国FDA核准，用于检测pMMR子宫内膜癌患者和符合默沙东免疫疗法Keytruda治疗条件的dMMR固体癌患者。 VENTANA MMR RxDx 面板的核准是该公司最近推出的面板标籤的延伸。同样在 2021 年 12 月，西门子 Healthineers 与 Freenome 合作，扩展该公司现有的成像技术，以识别适合早期乳癌检测的新型标记物。

生物标誌物市场报告亮点

  • 由于药物发现和药物开发中越来越多地采用安全生物标记物，安全细分市场在 2023 年占据最大的销售份额，达到 37.62%。
  • 由于促进研究活动的策略合作的增加，功效生物标记领域预计将从 2024 年到 2030 年以最快的复合年增长率增长。
  • 由于市场参与企业的广泛研发努力以及药物发现中生物标记的日益采用，药物发现和开发领域在 2023 年占据市场主导地位。
  • 肿瘤学领域预计将在 2023 年引领市场，并在 2024 年至 2030 年保持主导地位。然而，神经系统疾病领域预计在预测期内复合年增长率最快。
  • 由于主要企业的投资增加以及该地区疾病盛行率的增加，预计亚太地区将在 2024 年至 2030 年实现最快的复合年增长率。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章生物标记市场：变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 生物标誌物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析

第四章生物标记市场：类型估计和趋势分析

  • 类型市场占有率，2023年及2030年
  • 细分仪表板
  • 按类型分類的全球生物标记市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第五章生物标记市场：产品估算与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 按产品分類的全球生物标誌物市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第六章生物标记市场：应用估算与趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 按应用分類的全球生物标誌物市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第七章生物标记市场：疾病估计与趋势分析

  • 2023年及2030年疾病市场占有率
  • 细分仪表板
  • 按疾病分類的全球生物标记市场前景
  • 2018年至2030年市场规模、预测与趋势分析

第八章生物标记市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Epigenomics AG
    • General Electric
    • Johnson &Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • QIAGEN
    • Merck KGaA
    • PerkinElmer Inc.
    • Agilent Technologies, Inc.
    • Eurofins Scientific
Product Code: 978-1-68038-979-1

Biomarkers Market Growth & Trends:

The global biomarkers market size is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck's immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company's recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights:

  • The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
  • The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
  • The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
  • The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030. . However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
  • Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Application
    • 1.2.4. Disease
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for Primary Interviews in Europe
      • 1.4.5.3. Data for Primary Interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type and product outlook
    • 2.2.2. Application and disease outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing funding for biomarkers
      • 3.2.1.2. Increasing prevalence for chronic diseases
      • 3.2.1.3. Technological advancement
      • 3.2.1.4. Growing importance of companion diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of reimbursement policies for biomarkers
      • 3.2.2.2. High capital investment and lengthy timelines for biomarker development
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Emergence of personalized medicine
      • 3.2.3.2. Emerging economies
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Challenges associated with biomarkers validation
      • 3.2.4.2. Technical issues related to sample collection and storage
  • 3.3. Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
      • 3.3.3.1. Selling price of biomarker by top players

Chapter 4. Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Biomarkers Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Safety biomarkers
      • 4.4.1.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Efficacy biomarkers
      • 4.4.2.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Predictive biomarkers
      • 4.4.3.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Surrogate biomarkers
      • 4.4.4.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Pharmacodynamic biomarkers
      • 4.4.5.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Prognostics biomarkers
      • 4.4.6.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Validation biomarkers
      • 4.4.7.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biomarkers Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Biomarkers Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Consumables
      • 5.4.1.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Services
      • 5.4.2.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Software
      • 5.4.3.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Biomarkers Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Diagnostics
      • 6.4.1.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.2. Drug Discovery and Development
      • 6.4.2.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Personalized Medicine
      • 6.4.3.1. Personalized medicine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.4. Disease Risk Assessment
      • 6.4.4.1. Disease risk assessment market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

  • 7.1. Disease Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Biomarkers Market by Disease Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Cancer
      • 7.4.1.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.2. Safety biomarkers
      • 7.4.1.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.3. Efficacy biomarkers
      • 7.4.1.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.4. Predictive biomarkers
      • 7.4.1.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.5. Surrogate biomarkers
      • 7.4.1.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.6. Pharmacodynamic biomarkers
      • 7.4.1.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.7. Prognostics biomarkers
      • 7.4.1.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.8. Validation biomarkers
      • 7.4.1.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2. Cardiovascular Diseases
      • 7.4.2.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.2. Safety biomarkers
      • 7.4.2.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.3. Efficacy biomarkers
      • 7.4.2.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.4. Predictive biomarkers
      • 7.4.2.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.5. Surrogate biomarkers
      • 7.4.2.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.6. Pharmacodynamic biomarkers
      • 7.4.2.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.7. Prognostics biomarkers
      • 7.4.2.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.8. Validation biomarkers
      • 7.4.2.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)Neurological Diseases
      • 7.4.3.1. Neurological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.2. Safety biomarkers
      • 7.4.3.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.3. Efficacy biomarkers
      • 7.4.3.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.4. Predictive biomarkers
      • 7.4.3.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.5. Surrogate biomarkers
      • 7.4.3.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.6. Pharmacodynamic biomarkers
      • 7.4.3.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.7. Prognostics biomarkers
      • 7.4.3.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.8. Validation biomarkers
      • 7.4.3.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4. Immunological Diseases
      • 7.4.4.1. Immunological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.2. Safety biomarkers
      • 7.4.4.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.3. Efficacy biomarkers
      • 7.4.4.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.4. Predictive biomarkers
      • 7.4.4.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.5. Surrogate biomarkers
      • 7.4.4.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.6. Pharmacodynamic biomarkers
      • 7.4.4.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.7. Prognostics biomarkers
      • 7.4.4.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.8. Validation biomarkers
      • 7.4.4.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.2. Safety biomarkers
      • 7.4.5.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.3. Efficacy biomarkers
      • 7.4.5.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.4. Predictive biomarkers
      • 7.4.5.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.5. Surrogate biomarkers
      • 7.4.5.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.6. Pharmacodynamic biomarkers
      • 7.4.5.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.7. Prognostics biomarkers
      • 7.4.5.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.8. Validation biomarkers
      • 7.4.5.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key Country Dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. F. Hoffmann-La Roche Ltd.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Abbott
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Epigenomics AG
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. General Electric
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Johnson & Johnson Services, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Thermo Fisher Scientific Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Bio-Rad Laboratories, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Siemens Healthineers AG
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. QIAGEN
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Merck KGaA
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. PerkinElmer Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Agilent Technologies, Inc.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Eurofins Scientific
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 North America Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 6 North America Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 North America Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 U.S. Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 12 Canada Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 16 Europe Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 21 Germany Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Germany Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 Germany Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Germany Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 25 UK Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 UK Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 UK Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 UK Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 29 France Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 France Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 31 France Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 33 Spain Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Spain Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Spain Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 37 Italy Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Italy Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 40 Italy Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 41 Denmark Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 43 Denmark Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Denmark Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 45 Norway Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Norway Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 49 Sweden Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 51 Sweden Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Sweden Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 58 Japan Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Japan Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 Japan Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 Japan Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 62 China Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 China Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 China Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 65 China Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 66 India Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 India Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 68 India Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 India Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 70 South Korea Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 71 South Korea Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 72 South Korea Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 South Korea Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 74 Australia Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Australia Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 Australia Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Australia Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 78 Thailand Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Thailand Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 80 Thailand Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 81 Thailand Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 82 Latin America Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 83 Latin America Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 84 Latin America Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 85 Latin America Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 87 Brazil Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Brazil Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 89 Brazil Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 Brazil Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 91 Argentina Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 Argentina Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 93 Argentina Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 Argentina Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 95 Mexico Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 97 Mexico Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 98 Mexico Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East and Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 104 South Africa Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 South Africa Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 106 South Africa Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 112 Kuwait Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 113 Kuwait Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 114 Kuwait Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 116 UAE Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 117 UAE Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 118 UAE Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 119 UAE Biomarkers Market, By Disease, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary Interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary Interviews in APAC
  • Fig. 7 Primary Interviews in Latin America
  • Fig. 8 Primary Interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Biomarkers market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Biomarkers market driver impact
  • Fig. 20 Biomarkers market restraint impact
  • Fig. 21 Biomarkers market strategic initiatives analysis
  • Fig. 22 Biomarkers market: Type movement analysis
  • Fig. 23 Biomarkers market: Type outlook and key takeaways
  • Fig. 24 Safety biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 25 Efficacy biomarkers agents estimates and forecast, 2018 - 2030
  • Fig. 26 Predictive biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 27 Surrogate biomarkers estimates and forecast, 2018 - 2030
  • Fig. 28 Pharmacodynamic biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 29 Prognostics biomarkers estimates and forecast, 2018 - 2030
  • Fig. 30 Validation biomarkers estimates and forecast, 2018 - 2030
  • Fig. 31 Biomarkers market: Product movement analysis
  • Fig. 32 Biomarkers market: Product outlook and key takeaways
  • Fig. 33 Consumables market estimates and forecast, 2018 - 2030
  • Fig. 34 Services estimates and forecast, 2018 - 2030
  • Fig. 35 Software market estimates and forecast, 2018 - 2030
  • Fig. 36 Biomarkers market: Disease movement analysis
  • Fig. 37 Biomarkers market: Disease outlook and key takeaways
  • Fig. 38 Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 39 Drug discovery and development estimates and forecast, 2018 - 2030
  • Fig. 40 Personalized medicine market estimates and forecast, 2018 - 2030
  • Fig. 41 Disease risk assessment estimates and forecast, 2018 - 2030
  • Fig. 42 Others market estimates and forecast, 2018 - 2030
  • Fig. 43 Biomarkers market: Disease movement analysis
  • Fig. 44 Biomarkers market: Disease outlook and key takeaways
  • Fig. 45 Cancer market estimates and forecast, 2018 - 2030
  • Fig. 46 Cardiovascular diseases estimates and forecast, 2018 - 2030
  • Fig. 47 Neurological diseases market estimates and forecast, 2018 - 2030
  • Fig. 48 Immunological diseases estimates and forecast, 2018 - 2030
  • Fig. 49 Others market estimates and forecast, 2018 - 2030
  • Fig. 50 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 51 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 52 Global ophthalmic drugs market share and leading players
  • Fig. 53 North America market share and leading players
  • Fig. 54 Europe market share and leading players
  • Fig. 55 Asia Pacific market share and leading players
  • Fig. 56 Latin America market share and leading players
  • Fig. 57 Middle East & Africa market share and leading players
  • Fig. 58 North America: SWOT
  • Fig. 59 Europe SWOT
  • Fig. 60 Asia Pacific SWOT
  • Fig. 61 Latin America SWOT
  • Fig. 62 MEA SWOT
  • Fig. 63 North America, by country
  • Fig. 64 North America
  • Fig. 65 North America market estimates and forecasts, 2018 - 2030
  • Fig. 66 U.S. key country dynamics
  • Fig. 67 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 68 Canada key country dynamics
  • Fig. 69 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 72 UK key country dynamics
  • Fig. 73 UK market estimates and forecasts, 2018 - 2030
  • Fig. 74 Germany key country dynamics
  • Fig. 75 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 76 France key country dynamics
  • Fig. 77 France market estimates and forecasts, 2018 - 2030
  • Fig. 78 Italy key country dynamics
  • Fig. 79 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 80 Spain key country dynamics
  • Fig. 81 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 82 Denmark key country dynamics
  • Fig. 83 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 84 Sweden key country dynamics
  • Fig. 85 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 86 Norway key country dynamics
  • Fig. 87 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 90 China key country dynamics
  • Fig. 91 China market estimates and forecasts, 2018 - 2030
  • Fig. 92 Japan key country dynamics
  • Fig. 93 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 94 India key country dynamics
  • Fig. 95 India market estimates and forecasts, 2018 - 2030
  • Fig. 96 Thailand key country dynamics
  • Fig. 97 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 98 South Korea key country dynamics
  • Fig. 99 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 100 Australia key country dynamics
  • Fig. 101 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 104 Brazil key country dynamics
  • Fig. 105 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 106 Mexico key country dynamics
  • Fig. 107 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 108 Argentina key country dynamics
  • Fig. 109 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 110 Middle East and Africa
  • Fig. 111 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 112 South Africa key country dynamics
  • Fig. 113 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 114 Saudi Arabia key country dynamics
  • Fig. 115 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 116 UAE key country dynamics
  • Fig. 117 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 118 Kuwait key country dynamics
  • Fig. 119 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 120 Market share of key market players- Biomarkers market